Stocks and Investing Stocks and Investing
Fri, December 22, 2023
Thu, December 21, 2023

Paul Matteis Reiterated (BMRN) at Strong Buy and Held Target at $101 on, Dec 21st, 2023


Published on 2024-10-28 08:06:17 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Reiterated "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy and Held Target at $101 on, Dec 21st, 2023.

Paul has made no other calls on BMRN in the last 4 months.



There are 11 other peers that have a rating on BMRN. Out of the 11 peers that are also analyzing BMRN, 3 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Tuesday, November 7th, 2023
  • William Pickering of "Bernstein" Upgraded from Sell to Hold and Held Target at $82 on, Monday, October 23rd, 2023
  • Laura Chico of "Raymond James" Initiated at Hold on, Thursday, September 28th, 2023


These are the ratings of the 8 analyists that currently disagree with Paul


  • Kostas Biliouris of "BMO Capital" Maintained at Buy with Decreased Target to $100 on, Friday, November 3rd, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $115 on, Thursday, November 2nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $117 on, Thursday, November 2nd, 2023
  • Olivia Brayer of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $100 on, Thursday, November 2nd, 2023
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $111 on, Thursday, November 2nd, 2023
  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $140 on, Monday, September 25th, 2023
  • Martin Auster of "UBS" Initiated at Strong Buy and Held Target at $120 on, Monday, September 18th, 2023
  • Debjit Chattopadhyay of "Guggenheim" Reiterated at Strong Buy and Held Target at $110 on, Wednesday, September 13th, 2023
Contributing Sources